Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 13, 2025
Product Development
Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation
How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity
BioCentury | Nov 8, 2024
Distillery Therapeutics
Sprayable nanorods delivering inflammasome inhibitors for psoriasis
BioCentury | Nov 4, 2024
Distillery Therapeutics
De novo designed miniproteins blocking IL-1 and IL-6 signaling for CRS
BioCentury | Oct 7, 2024
Distillery Therapeutics
Inhibiting trained immunity for post-stroke heart failure
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Aug 27, 2024
Emerging Company Profile
Montai: Mapping chem-bio connections to find human-vetted therapies
Flagship company uses in silico screening to mine ‘Anthromolecules’ as starting points for pills targeting well-validated pathways, with an initial focus on I&I
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Mar 29, 2024
Finance
Public equity report: Avalo gets makeover with PIPE, acquisition
Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
Items per page:
1 - 10 of 870